Show simple item record

dc.contributor.authorLamarca, Angela
dc.contributor.authorEdeline, J.
dc.contributor.authorGoyal, L.
dc.date.accessioned2022-02-22T11:44:39Z
dc.date.available2022-02-22T11:44:39Z
dc.date.issued2022en
dc.identifier.citationLamarca A, Edeline J, Goyal L. How I treat biliary tract cancer. Vol. 7, ESMO Open. Elsevier BV; 2022. p. 100378.en
dc.identifier.pmid35032765en
dc.identifier.doi10.1016/j.esmoop.2021.100378en
dc.identifier.urihttp://hdl.handle.net/10541/625067
dc.description.abstractManagement of biliary tract cancers (BTCs) is rapidly evolving. Curative management relies on surgical resection followed by adjuvant capecitabine for cholangiocarcinoma and gallbladder cancers. Unfortunately relapse rate remains high, and better adjuvant strategies are urgently required. A majority of patients are diagnosed with advanced disease, when chemotherapy with cisplatin and gemcitabine followed by second-line 5-FU and oxaliplatin / irinotecan is the cornerstone of treatment for most patients in the absence of targetable alterations. Targeted therapies, including therapies for tumours with fibroblast growth factor receptor-2 (FGFR-2) fusions, isocitrate dehydrogenase-1 (IDH-1) mutations, B-Raf proto-oncogene serine/threonine kinase (BRAF) V600E mutations, neurotrophic tyrosine receptor kinase (NTRK) fusions, Human epidermal growth factor-2 (HER-2) amplifications, and/ or microsatellite instability are rapidly changing the treatment paradigm for many patients with advanced BTC, especially for patients with intrahepatic cholangiocarcinoma. Because of this, molecular profiling should be considered early on patients pathway to allow adequate planning of therapy. Ongoing research is likely to clarify the role of immunotherapy, liver-directed therapy, and liver transplant for BTCs in the future.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.esmoop.2021.100378en
dc.titleHow I treat biliary tract canceren
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK. Electronic address: angela.lamarca@nhs.net. Department of Medical Oncology, Centre Eugène Marquis, Rennes, France. Department of Medical Oncology, Mass General Cancer Center, Harvard Medical School, Boston, USA.en
dc.identifier.journalESMO Openen
dc.description.noteen]
refterms.dateFOA2022-04-20T11:32:18Z


Files in this item

Thumbnail
Name:
Lamarca.pdf
Size:
1.170Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record